IP Verse

Cell Line Expressing Single Chain Factor Viii Polypeptides And Uses Thereof

PatentPatent Analysis

EP2870250

BIOGEN IDEC MA
Application Number
EP13813225A
Filing Date
Jul 5, 2013
Status
Patent Maintained As Amended
May 27, 2022
Grant Date
Jun 29, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2645106B2
EP2701778B2
EP2653873B8

Bibliography

The patent EP2870250B2 was granted to Biogen Idec MA on Jun 29, 2022 following the initial filing on Jul 5, 2013 under the application number EP13813225A . The current legal status of the patent is Patent Maintained As Amended.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

EUROPEAN OPPOSITIONSJan 18, 2019ADMISSIBLE
FH SERVICESJan 17, 2019ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents